Quantum Biopharma Reports unbuzzd Clinical Trial Success

February 4, 2025

DENVER, Colo., Feb 04, 2025 (247marketnews.com)- Quantum BioPharma (NASDAQ:QNTM) announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, unbuzzd, on alcohol intoxication and metabolism. The results showed that unbuzzd significantly accelerated the reduction of blood alcohol concentration (BAC), reducing it over 40% faster within 30 minutes compared to a placebo.

Trial participants reported improvements in alertness and reduced perceived impairment. furthermore, and lessened hangover symptoms, including a 67% reduction in headache severity.

Dr. Andrzej Chruscinski, Quantum’s VP of Clinical and Scientific Affairs, stated, “We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd to help reduce the acute effects of alcohol intoxication. We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”

unbuzzd was reported to be well-tolerated with no adverse effects reported. It also helped stabilize heart rate and blood pressure, which are typically affected by alcohol intoxication. The formula, licensed to Celly Nutrition Corp., is available for purchase and aims to aid responsible alcohol consumption by speeding BAC reduction and alleviating the effects of intoxication and hangovers.

Zeeshan Saeed, Quantum’s CEO, added, “This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover.”

The global hangover cure products market was expected to reach approximately $1.56 billion in 2024, offering a significant market opportunity. unbuzzd stands out with its clinically proven efficacy, which sets it apart from competitors that often lack strong clinical validation. The product’s rapid onset of action and its ability to provide comprehensive symptom relief, including faster BAC reduction and alleviation of hangover symptoms, address key consumer pain points. This combination of speed and effectiveness gives unbuzzd a competitive edge in the growing hangover remedy market.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (QNTM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.